Zolpidem for Persistent Insomnia in SSRI-Treated Depressed Patients

Asnis, Gregory M.; Chakraburtty, Amal; DuBoff, E.; Krystal, Andrew D.; Londborg, Peter D.; Rosenberg, Russell; Roth-Schechter, Barbara F.; Scharf, Martin B.; Walsh, James K.

doi:10.4088/jcp.v60n1005

Cited by 161 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Agomelatine may prove to be a useful antidepressant for patients with enduring sleep problems. The addition of a GABA-ergic hypnotic such as zolpidem (Asnis et al 1999) or escopiclone (Fava et al 2006) also appears to improve both sleep and mood outcomes in the short term, although the possibly increased incidence of depression on hypnotics (Kripke, 2007) warrants caution. Finally, cognitive behavioral therapy for insomnia (CBT-I), which combines behavioral approaches (relaxation training, stimulus control, sleep restriction) with a cognitive intervention targeting negative beliefs about sleep, is effective and may be superior to hypnotics in primary insomnia (Jacobs et al, 2004;Sivertsen et al, 2006).…”

Section: Treatment Implicationsmentioning

confidence: 99%

Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

Dombrovski¹,

Cyranowski²,

Mulsant³

et al. 2008

Depress. Anxiety

103

View full text Add to dashboard Cite

Background-Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression.

show abstract

Section: Treatment Implicationsmentioning

confidence: 99%

Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

Dombrovski¹,

Cyranowski²,

Mulsant³

et al. 2008

Depress. Anxiety

103

View full text Add to dashboard Cite

show abstract

“…Statistical analysis is more appropriate when using a larger group size and when ranking the severity of the observed parameters, but even so, when Markgraf et al (2010) Pharmacological effects identified during FOB may differ between adult and juvenile animals (Himmel, 2008), justifying careful designs supported by regulatory guidance documents (EMEA, 2008;FDA, 2006) to investigate possible neurotoxicity in a younger population when applicable. Authier et al 2015JPTM 6/2/2016 A wide range of approved drugs are associated with drug induced sleep disturbances such as insomnia, including beta-blockers (Chang et al, 2013;Moser, 1979), corticosteroids (Ciriaco et al, 2013), selective serotonin-reuptake inhibitors (SSRI) (Asnis, et al, 1999) or acetylcholinesterase inhibitors (Cooke et al, 2006). Polysomnography is a well-established technique for sleep disturbance assessment and is well established in laboratory animal species commonly used for non-clinical drug SP testing including rodents (Gotter et al, 2013), dogs and non-human primates (Authier et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Safety Pharmacology Investigations on the Nervous System: An Industry Survey

Authier

2017

Journal of Pharmacological and Toxicological Methods

View full text Add to dashboard Cite

Abstract:The Safety Pharmacology Society (SPS) conducted an industry survey in 2015 to identify industry practices as they relate to central, peripheral and autonomic nervous system ("CNS") drug safety testing. One hundred fifty-eight (158) participants from Asia (16%), Europe (20%) and North America (56%) responded to the survey. 52% of participants were from pharmaceutical companies (>1,000 employees). Oncology (67%) and neurology/psychiatry (66%) were the most frequent target indications pursued by companies followed by inflammation (48%), cardiovascular (43%), metabolic (39%), infectious (37%), orphan (32%) and respiratory (29%) diseases. Seizures (67% of participants), gait abnormalities (67%), tremors (65%), emesis (56%), sedation (52%) and salivation (47%) were the most commonly encountered CNS issues in pre-clinical drug development while headache (65%), emesis/nausea (60%), fatigue (51%) and dizziness (49%) were the most frequent issues encountered in Phase I clinical trials. 54% of respondents reported that a standard battery of tests applied to screen drug candidates was the approach most commonly used to address nonclinical CNS safety testing. A minority (14% of all participants) reported using electroencephalography (EEG) screening prior to animal inclusion on toxicology studies. The most frequent group size was n=8 for functional observation battery (FOB), polysomnography and seizure liability studies. FOB evaluations were conducted in a dedicated room (78%) by blinded personnel (66%) with control for circadian cycle (55%) effects (e.g., dosing at a standardized time; balancing time of day across treatment groups). The rat was reported as the most common species used for seizure liability, nerve conduction and drug-abuse liability testing.

show abstract

“…Bastien et al 99 compared individual-, group-, and telephone-delivered CBT-I. Mimeault et al included two arms that compared self-help CBT-I to self-help CBT-I with professional guidance.…”

Section: Comparative Effectiveness Of Psychological Treatmentsmentioning

confidence: 99%